ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Principal Associate Scientist, Analytical Development & Operations at Strand Therapeutics - ApplyBlast

Principal Associate Scientist, Analytical Development & Operations

Strand Therapeutics

5 days ago

Boston, Massachusetts, United States

Onsite

Full Time

Senior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

Strand Therapeutics is seeking a Principal Associate Scientist for Analytical Development & Operations to lead the development of analytical methods for mRNA and LNP formulations. The role involves analyzing data to drive process optimization, troubleshooting experimental challenges, and mentoring junior scientists. This position requires a strong scientific background and experience with analytical and process development in a dynamic, early-stage biotechnology environment.

Responsibilities

Lead development of analytical methods for mRNA and LNP formulations
Analyze data to drive screening, optimization, and scale-up efforts
Mentor junior scientists and troubleshoot experimental challenges

Skills

Qualifications

B.S. or Advanced Degree in Chemistry, Chemical Engineering, Biology, Biochemistry, Molecular Biology or other relevant scientific discipline

About Strand Therapeutics

strandtx.com

Headquarters

Boston, Massachusetts, United States

Company Size

51-200 employees

Founded

2017

View Profile

Strand Therapeutics is a clinical-stage biotechnology company developing programmable mRNA therapeutics for solid tumors, blood cancers, and autoimmune diseases. The company's platform addresses core challenges in genetic medicine—targeting, safety, and potency—through proprietary technologies including SignalPath LNPs for tissue-specific delivery, SignalLock RNA for microRNA-based mRNA encryption, and SignalScript RNA for enhanced potency and durability. Its pipeline includes STX-001 for solid tumors, STX-003 for systemic tumor delivery, and STX-005, a pioneering in vivo CAR-T approach for autoimmune diseases and blood cancers.